Literature DB >> 22004955

Cytotoxic activity of G3 PAMAM-NH₂ dendrimer-chlorambucil conjugate in human breast cancer cells.

Krzysztof Bielawski1, Anna Bielawska, Anna Muszyńska, Bożena Popławska, Robert Czarnomysy.   

Abstract

Evaluation of the cytotoxicity of a novel G3 PAMAM-NH(2) dendrimer-chlorambucil conjugate employing a MTT assay and inhibition of [(3)H]thymidine incorporation into DNA in both MDA-MB-231 and MCF-7 breast cancer cells demonstrated that the conjugate was more potent antiproliferative agent than chlorambucil. It was found that dendrimer-chlorambucil conjugate was more active inhibitor of collagen biosynthesis than chlorambucil. Our experiments carried out with flow cytometry assessment of annexin V binding and fluorescent microscopy assay revealed that PAMAM-CH conjugate inhibited the proliferation of MCF-7 and MDA-231 malignant cells by increasing the number of apoptotic and necrotic cells. The apoptotic effect of PAMAM-CH conjugate was found to be stronger than that caused by chlorambucil.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004955     DOI: 10.1016/j.etap.2011.08.002

Source DB:  PubMed          Journal:  Environ Toxicol Pharmacol        ISSN: 1382-6689            Impact factor:   4.860


  4 in total

1.  Chlorambucil Conjugated Ugi Dendrimers with PAMAM-NH₂ Core and Evaluation of Their Anticancer Activity.

Authors:  Nalin Seixas; Bruno B Ravanello; Ibrahim Morgan; Goran N Kaluđerović; Ludger A Wessjohann
Journal:  Pharmaceutics       Date:  2019-02-01       Impact factor: 6.321

2.  Effect of 2nd and 3rd generation PAMAM dendrimers on proliferation, differentiation, and pro-inflammatory cytokines in human keratinocytes and fibroblasts.

Authors:  Robert Czarnomysy; Anna Bielawska; Krzysztof Bielawski
Journal:  Int J Nanomedicine       Date:  2019-09-03

Review 3.  Nanodrug delivery in reversing multidrug resistance in cancer cells.

Authors:  Sonali Kapse-Mistry; Thirumala Govender; Rohit Srivastava; Mayur Yergeri
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

4.  Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity.

Authors:  Artin Assadi; Vahideh Sharifi Najafabadi; Seyed Ataollah Sadat Shandiz; Azadah Shayeq Boroujeni; Sepehr Ashrafi; Ali Zaman Vaziri; Seyedeh Masoumeh Ghoreishi; Mohammad Reza Aghasadeghi; Seyed Esmaeil Sadat Ebrahimi; Morteza Pirali-Hamedani; Mehdi Shafiee Ardestani
Journal:  Onco Targets Ther       Date:  2016-09-07       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.